Trial Profile
Renovascular safety of antiangiogenics
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jul 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Sunitinib (Primary)
- Indications Breast cancer; Prostate cancer
- Focus Adverse reactions
- Acronyms MARS
- 02 Jun 2015 Results in patients with prostate cancer receiving sunitinib presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 19 Dec 2014 New trial record